Skip to main content
placeholder image

Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD

Journal Article


Download full-text (Open Access)

Abstract


  • Neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are increasing in prevalence but lack targeted therapeutics. Although the pathological mechanisms behind these diseases remain unclear, both ALS and FTD are characterized pathologically by aberrant protein aggregation and inclusion formation within neurons, which correlates with neurodegeneration. Notably, aggregation of several key proteins, including TAR DNA binding protein of 43 kDa (TDP-43), superoxide dismutase 1 (SOD1), and tau, have been implicated in these diseases. Proteomics methods are being increasingly applied to better understand disease-related mechanisms and to identify biomarkers of disease, using model systems as well as human samples. Proteomics-based approaches offer unbiased, high-throughput, and quantitative results with numerous applications for investigating proteins of interest. Here, we review recent advances in the understanding of ALS and FTD pathophysiology obtained using proteomics approaches, and we assess technical and experimental limitations. We compare findings from various mass spectrometry (MS) approaches including quantitative proteomics methods such as stable isotope labeling by amino acids in cell culture (SILAC) and tandem mass tagging (TMT) to approaches such as label-free quantitation (LFQ) and sequential windowed acquisition of all theoretical fragment ion mass spectra (SWATH-MS) in studies of ALS and FTD. Similarly, we describe disease-related protein-protein interaction (PPI) studies using approaches including immunoprecipitation mass spectrometry (IP-MS) and proximity-dependent biotin identification (BioID) and discuss future application of new techniques including proximity-dependent ascorbic acid peroxidase labeling (APEX), and biotinylation by antibody recognition (BAR). Furthermore, we explore the use of MS to detect post-translational modifications (PTMs), such as ubiquitination and phosphorylation, of disease-relevant proteins in ALS and FTD. We also discuss upstream technologies that enable enrichment of proteins of interest, highlighting the contributions of new techniques to isolate disease-relevant protein inclusions including flow cytometric analysis of inclusions and trafficking (FloIT). These recently developed approaches, as well as related advances yet to be applied to studies of these neurodegenerative diseases, offer numerous opportunities for discovery of potential therapeutic targets and biomarkers for ALS and FTD.

UOW Authors


  •   Hedl, Thomas (external author)
  •   San Gil, Rebecca (external author)
  •   Cheng, Flora (external author)
  •   Rayner, Stephanie L. (external author)
  •   Davidson, Jennilee (external author)
  •   De Luca, Alana (external author)
  •   Villalva, Maria (external author)
  •   Ecroyd, Heath
  •   Walker, Adam K. (external author)
  •   Lee, Albert (external author)

Publication Date


  • 2019

Citation


  • Hedl, T. J., San Gil, R., Cheng, F., Rayner, S. L., Davidson, J. M., De Luca, A., Villalva, M. D., Ecroyd, H., Walker, A. K. & Lee, A. (2019). Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD. Frontiers In Neuroscience, 13 548-1-548-25.

Scopus Eid


  • 2-s2.0-85068512030

Ro Full-text Url


  • https://ro.uow.edu.au/cgi/viewcontent.cgi?article=1798&context=smhpapers1

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers1/784

Start Page


  • 548-1

End Page


  • 548-25

Volume


  • 13

Place Of Publication


  • Switzerland

Abstract


  • Neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are increasing in prevalence but lack targeted therapeutics. Although the pathological mechanisms behind these diseases remain unclear, both ALS and FTD are characterized pathologically by aberrant protein aggregation and inclusion formation within neurons, which correlates with neurodegeneration. Notably, aggregation of several key proteins, including TAR DNA binding protein of 43 kDa (TDP-43), superoxide dismutase 1 (SOD1), and tau, have been implicated in these diseases. Proteomics methods are being increasingly applied to better understand disease-related mechanisms and to identify biomarkers of disease, using model systems as well as human samples. Proteomics-based approaches offer unbiased, high-throughput, and quantitative results with numerous applications for investigating proteins of interest. Here, we review recent advances in the understanding of ALS and FTD pathophysiology obtained using proteomics approaches, and we assess technical and experimental limitations. We compare findings from various mass spectrometry (MS) approaches including quantitative proteomics methods such as stable isotope labeling by amino acids in cell culture (SILAC) and tandem mass tagging (TMT) to approaches such as label-free quantitation (LFQ) and sequential windowed acquisition of all theoretical fragment ion mass spectra (SWATH-MS) in studies of ALS and FTD. Similarly, we describe disease-related protein-protein interaction (PPI) studies using approaches including immunoprecipitation mass spectrometry (IP-MS) and proximity-dependent biotin identification (BioID) and discuss future application of new techniques including proximity-dependent ascorbic acid peroxidase labeling (APEX), and biotinylation by antibody recognition (BAR). Furthermore, we explore the use of MS to detect post-translational modifications (PTMs), such as ubiquitination and phosphorylation, of disease-relevant proteins in ALS and FTD. We also discuss upstream technologies that enable enrichment of proteins of interest, highlighting the contributions of new techniques to isolate disease-relevant protein inclusions including flow cytometric analysis of inclusions and trafficking (FloIT). These recently developed approaches, as well as related advances yet to be applied to studies of these neurodegenerative diseases, offer numerous opportunities for discovery of potential therapeutic targets and biomarkers for ALS and FTD.

UOW Authors


  •   Hedl, Thomas (external author)
  •   San Gil, Rebecca (external author)
  •   Cheng, Flora (external author)
  •   Rayner, Stephanie L. (external author)
  •   Davidson, Jennilee (external author)
  •   De Luca, Alana (external author)
  •   Villalva, Maria (external author)
  •   Ecroyd, Heath
  •   Walker, Adam K. (external author)
  •   Lee, Albert (external author)

Publication Date


  • 2019

Citation


  • Hedl, T. J., San Gil, R., Cheng, F., Rayner, S. L., Davidson, J. M., De Luca, A., Villalva, M. D., Ecroyd, H., Walker, A. K. & Lee, A. (2019). Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD. Frontiers In Neuroscience, 13 548-1-548-25.

Scopus Eid


  • 2-s2.0-85068512030

Ro Full-text Url


  • https://ro.uow.edu.au/cgi/viewcontent.cgi?article=1798&context=smhpapers1

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers1/784

Start Page


  • 548-1

End Page


  • 548-25

Volume


  • 13

Place Of Publication


  • Switzerland